Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
This will be a pilot trial evaluating the safety and immunogenicity of the WT-1 peptide
vaccine in patients with hematologic malignancies. Ten patients with acute myelogenous
leukemia (AML) or advanced myelodysplastic syndrome (MDS), will be enrolled. Patients will
be vaccinated with a preparation of WT-1-derived native and synthetic peptides plus
immunologic adjuvant Montanide ISA 51 VG (Seppic Pharmaceuticals, Fairfield, NJ) and
Sargramostim (GM-CSF). One dose level will be tested.
Patients will receive 6 injections of the WT-1 vaccine. Doses will be given every 2 weeks.
Each vaccine is given at a different location under the skin in the arm or leg. Patients
will be monitored for 30 minutes after vaccination.
WT-1 vaccine is given with another substance, Montanide, which clumps the WT-1 vaccine and
improves the immune response. Patients will also receive an injection of Sargramostim
(GM-CSF) 2 days before each vaccination and again on the day of the WT-1 injection at the
same spot. Sargramostim (GM-CSF) stimulates the body's white blood cells to boost the immune
response. Patients may be taught to do the Sargramostim (GM-CSF) injection themselves in
which case patients will be given a log sheet to record the injection time and location. If
not, they will need to come for an additional 24 study visits.
To monitor their health while receiving the vaccine, patients will need the following tests
and procedures as a part of regular cancer care.
- History and physical examination every 2 weeks
- Complete blood count (CBC) and comprehensive panel every 2 weeks
- Bone marrow aspirate at week 14 for patients with acute myelogenous leukemia or
Patients will need these tests and procedures to see whether the vaccine is causing an
- A skin test will be performed before patients start the study and again in the 8th and
14th weeks in which a small amount of the vaccine will be placed under the skin. Two
days later, the site will be checked to see whether a bump or swelling has formed.
Another substance which typically does cause a mild reaction (mumps) will also be
placed under the skin to measure whether they have a normal immune reaction.
- We will take about 7 tablespoons of blood to measure their immune response. About 1
tablespoon of blood will be taken to measure the levels of WT-1 in their blood. Blood
samples will be taken prior to receiving the first vaccination and prior to receiving
the vaccination at weeks 6 and 12.
If the vaccine causes the patient to have an immune response, and their cancer does not
grow, they may continue to receive the WT-1 vaccinations monthly for 6 more months. If this
occurs, the patient will have a computed tomography (CT) scan or bone marrow test and
immunology blood tests 2 weeks after the 9th and 12th vaccinations.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Adverse Events (AEs)
Toxicities will be tabulated according to the NCI Common Toxicity (version 3.0) by grade and category. If more than one patients develops ≥ grade 3 non-hematologic toxicity or grade 4 hematologic toxicity, the study accrual will be suspended immediately for a careful toxicity data evaluation. Depending upon the findings of such safety/toxicity data assessment and consultation with the supporting pharmaceutical company, the principal investigator of this trial will have the option of terminating this trial permanently, amending the study protocol, or resuming the patient accrual.
12 weeks to 6 months
Jeffrey Lancet, M.D.
H. Lee Moffitt Cancer Center and Research Institute
United States: Institutional Review Board
|H. Lee Moffitt Cancer Center and Research Institute||Tampa, Florida 33612|